biological source
synthetic
Quality Level
form
powder
suitability
suitable for manufacturing use
storage temp.
−20°C
SMILES string
CN(Cc1cnc2nc(N)nc(N)c2n1)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O
InChI
1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
InChI key
FBOZXECLQNJBKD-ZDUSSCGKSA-N
Gene Information
human ... DHFR(1719)
General description
我们用于生物制药加工的SAFC® 系列优质原料经过严格的质量控制流程,配合记录文件和技术专长帮助我们的客户达到M-Clarity Program规定的要求。
M-Clarity Program
我们全面的上游工艺化学品系列不仅为生物制药生产商提供生产传统和创新治疗药物所需的优质原料,而且帮助他们更快地将产品投放市场并简化监管问题。请相信我们能够为您带来透明的供应链和可靠的全球采购能力,以最佳的法规支持和服务简化您的产品认证。
M-Clarity Program
我们全面的上游工艺化学品系列不仅为生物制药生产商提供生产传统和创新治疗药物所需的优质原料,而且帮助他们更快地将产品投放市场并简化监管问题。请相信我们能够为您带来透明的供应链和可靠的全球采购能力,以最佳的法规支持和服务简化您的产品认证。
抑制胸苷酸合成酶,是一种非选择性的嘌呤从头合成抑制剂,具有显著的毒性特征,包括肝毒性、肺炎和骨髓抑制。强效叶酸拮抗剂。在HL-60人白血病细胞中诱导凋亡。还可用作抗肿瘤剂。
Legal Information
SAFC is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under 甲氨蝶呤
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Muta. 2 - Repr. 1B - STOT RE 1
target_organs
Liver,Bone marrow
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
flash_point_f
Not applicable
flash_point_c
Not applicable
Roy Fleischmann et al.
Annals of the rheumatic diseases, 74(6), 1132-1137 (2014-08-22)
Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis disease activity; however, values for remission and low disease activity (LDA) for DAS28-CRP have not been validated.
Christian S Kaas et al.
Biotechnology journal, 10(7), 1081-1089 (2015-05-13)
Coagulation factor VIII (FVIII) is one of the most complex biopharmaceuticals due to the large size, poor protein stability and extensive post-translational modifications. As a consequence, efficient production of FVIII in mammalian cells poses a major challenge, with typical yields
Anna-Birgitte Aga et al.
Annals of the rheumatic diseases, 74(2), 381-388 (2013-11-29)
To investigate whether baseline disease activity levels and responses in patients with rheumatoid arthritis (RA) changed during the period 2000-2010. Data were provided by the Norwegian disease-modifying antirheumatic drug (NOR-DMARD) study. Patients with inflammatory joint diseases starting new treatment with
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| M7824-1G | 04061826004821 |
| M7824-5G | 04061832608563 |

